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Abstract 
Eukaryotic cells utilize DcpS, a scavenger decapping enzyme to degrade the residual 
cap structure following the 3’ to 5’ mRNA decay, thereby preventing the premature 
decapping of the capped long mRNA and misincorporation of methylated nucleotides 
in nucleic acids. Human DcpS was cloned and expressed as GST-fusion protein. The 
recombinant protein was purified and crystallized. Three dimensional structures of 
DcpS in ligand-free form and in complex with m7GDP were solved by X-ray 
crystallography method. Comparisons of these two structures and known structure of 
DcpS in complex with cap m7GpppG showed conformational changes in different 
enzyme state. apo-DcpS is a symmetric dimer, strikingly different from the 
asymmetric dimer observed in the structures of DcpS with bound cap analogues. 
DcpS with bound m7GDP is an asymmetric dimer in which the closed state appears to 
be the substrate-bound complex whereas the open state mimics the product-bound 
complex. Structural comparisons combined with mutational analysis suggest a 
dynamic mechanism for scavenger mRNA decapping. 
Keywords: X-ray crystallography; protein structure; mRNA decay; mRNA decapping; 




mRNA turnover plays important role in gene regulation. Decapping is an 
essential step in mRNA turnover. In the 5’ to 3’ decay pathway, the deadenylated 
mRNA was decapped by Dcp1/Dcp2 complex to release m7GDP and 5’-
phosphated RNA. An alternative pathway exists where a complex of exosome 
degrades the mRNA in a 3’ to 5’ direction. The remaining residual cap structure is 
degraded by DcpS, a scavenger decapping enzyme. DcpS specifically hydrolyzes 
7-methyl guanine cap structure attached to mRNA with less than 10 nucleotides, 
thereby preventing it from prematurely decapping the capped mRNA (Liu et al, 
2002). Consistent with its role in 3’ to 5’ mRNA decay, DcpS has been shown to 
be associated with a subset of exosome proteins in vivo (Wang and Kiledjian, 
2001). DcpS activity has also been implicated in the 5’ to 3’ decay pathway due to 
its susceptibility to m7GDP competition and activity against m7GDP in a reaction 
that release phosphate and m7GMP (van Dijk et al, 2003). Interestingly, DcpS 
was able to bind the cap structure of capped long RNA although it cannot 
hydrolyze it (Liu et al, 2004).  
To gain an insight view into the catalytic mechanism of decapping process 
Three dimensional structures of human DcpS in ligand-free form and in complex 
with m7GDP were solved by X-ray crystallography method. 
Apo-hDcpS enzyme exists as a symmetric homodimer structure. The apo-
hDcpS contains two distinct domains, a dimeric C-terminal domain and a 
swapped dimeric N-terminal domain. The N and C-terminal domains are 
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covalently connected through a hinged linker. The active HIT motif is located in 
the C-terminal domain and each protomer contains one substrate binding pocket. 
No interactions were seen between N and C-terminal domains in the apo-DcpS 
structure.  
Large conformation change in hDcpS occurred upon substrates binding. 
hDcpS dimer appears to be strikingly asymmetric both in our m7GDP binding 
state and the reported hDcpS mutant (H277N) in complex with m7GpppG (Gu et 
al., 2004). There is no substantial conformational change in the C-terminal 
domain while the swapped N-dimer acted as a rigid body and rotated 37o with 
respect to the C-terminal domain. This rotation simultaneously created open and 
closed conformation on opposite sides of the dimer. In addition to the overall 
structure change, significant positional shifts of several loop structures around the 
cap-binding cleft were also observed. They all moved inside toward the cleft and 
helped to coordinate the cap analog better.  
When comparing the structures of apo-DcpS, m7GDP-DcpS and m7GpppG-
DcpS, Tyr273 was noticed for its obvious changes on side-chain direction. To 
further identify the role of Tyr273, Tyr273 was mutated to Phe or Ala and mutant 
proteins were used for decapping activity assay. Mutant Y273A protein has <20% 









1.1 Messenger RNA turnover 
 
1.1.1 Biological significance of mRNA decay 
Messenger RNA decay is an essential step in post-transcriptional regulation of 
gene expression. In general, an mRNA transcript is continuously translated before 
its degradation. As a result, the level of a particular mRNA determines the 
abundance of its corresponding protein product. The amount of a given mRNA 
depends on the balance between its rates of synthesis and degradation. Thus 
mRNA decay provides a control point for gene expression regulation. The life 
time of mRNAs varies broadly and can be readily regulated in response to the 
environmental change. Moreover, gene expression patterns during development 
can be regulated by controlling mRNA stabilities (Wilusz, C. J. el al, 2004). In 
addition to general mRNA degradation pathways that function to remove old 
transcripts, there are several specialized mRNA decay pathways, which serve as 
the quality control of mRNA bio-synthesis. Abnormal mRNA transcripts can be 
recognized and degraded by these surveillance processes (Wagner & Lykke-
Andersen, 2002). mRNA surveillance is biologically important since the products 
of the abnormal transcripts are potentially deleterious to the cells. Finally, mRNA 
decay can be triggered by double-stranded RNA (miRNA or siRNA) highly 
homologous to their target RNA through a conserved mechanism called RNA 
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interference (RNAi), which plays important roles in gene expression regulation, 
development and antiviral defense (Dykxhoorn et al, 2003). 
 
1.1.2 General mRNA decay pathways 
 One distinct feature of eukaryotic mRNA is its modification at both 5’ and 3’ 
ends. A methylated cap structure is covalently conjugated to the first nucleotide of 
an mRNA at the 5’ end through an unusual 5’-5’ triphosphate linkage (Fig 1). A 
poly(A) tail is added to the 3’ end of the eukaryotic mRNA. Both modifications 
play important roles in the interactions between mRNAs and their regulatory 
protein factors, thus affecting various aspects of mRNA metabolism such as 










Gu M & Lima CD, Curr opin Struct Biol 15:99-106 
Fig 1. Eukaryotic mRNA Cap structure: An N7 methylated cap structure is 
covalently conjugated to the first nucleotide of an mRNA at the 5’ end through a 
special 5’-5’ triphosphate linkage 
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There are two general exonucleolytic mRNA decay pathways in eukaryotic 
cells according to the directions of degradation. In one pathway, mRNA is 
degraded from 5’ to 3’ direction while in the other pathway; it is degraded from 3’ 
to 5’ direction (Fig 2). Yeast and mammalian cells use both pathways but with 
different preference. For example, the 5’ to 3’ decay pathway predominates in 
yeast while the 3’ to 5’ decay pathway is the major pathway in mammals (Parker 
& Song, 2004). Both pathways are initiated by a common process called 
deadenylation, which shortens the 3’ poly(A) tail. Different exonucleolytic 
enzymes have been identified for this activity. In yeast, Ccr4p/Pop2p are major 
enzymes responsible for deadenylation (Tucker M. et al 2002, Daugeron et al, 
2001), and the Pan2p/Pan3p complex also has deadenylation activity (Hammet A 
et al, 2002). In mammalian cells, PARN, a poly(A) specific exonuclease degrades 
the poly(A) tail (Dehlin et al, 2000). Most of these deadenylase are conserved in 
eukaryotes, but they have different preference for mRNP substrates. An intact 
poly(A) tail is essential for maintaining the mRNA stability. After the poly(A) tail 
is degraded, mRNA will exit from the active translation status (see below). The 
translation machinery that associates with the mRNA will dissociate and expose 
the 5’ cap for degradation (Jacobson & Peltz, 1996). Thus the poly (A) tail is 
required to prevent the removal of the 5’ cap. In the 5’ to 3’ decay pathway, 
deadenylation is immediately followed by decapping. The exposed 5’ cap is 
hydrolyzed by the Dcp1p/Dcp2p complex in yeast, or Dcp2 alone in mammals 
(Parker & Song, 2004). The decapping enzyme generates a 5’-
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monophosphorylated mRNA (pRNA), which will be degraded by the cytoplasmic 
exonucleolytic enzyme Xrn1 from 5’ to 3’ direction (Muhlrad et al, 1994).  
In the 3’ to 5’ decay pathway that prevails in mammalian cells, a large protein 
complex called exosome degrades the mRNA body from 3’ to 5’ after the 
deadenylation (Mukherjee et al, 2002). Exosome contains a core complex of nine 
exonucleases and several other associated proteins (Butler, 2002). Based on EM 
reconstruction and homologous modeling, exosome has been predicted to form a 
ring-like structure similar to bacterial polynucleotide phosphorylase (PNPase) 
(Aloy et al, 2002). Exosome can be recruited to mRNA body through different 
means. In general mRNA decay pathways, a Ski complex containing Ski2, Ski3, 
and Ski8, wherein Ski2 is a DEAD-box RNA helicase which interacts with 
mRNA, Ski3 and Ski8 are adaptor proteins, can recruit exosome to mRNAs 
through another adaptor protein Ski7 (Araki et al, 2001). Exosome can also be 
recruited to mRNAs by specific RNA binding proteins (Gherzi et al, 2004). It has 
been shown that mRNAs containing AU-rich element (ARE) in their 3’- 
untranslated region (3’-UTR) are highly unstable (Chen et al, 2001). Recent 
results demonstrate that ARE-binding proteins can recruit exosome to mRNA for 
rapid mRNA degradation (Chen et al, 2001; Gherzi et al, 2004; Mukherjee et al, 
2002). Finally, the residue cap structure following the 3’ to 5’ decay is hydrolyzed 
by the decapping enzyme DcpS (Fillman & Lykke-Andersen, 2005). 
Eukaryotic mRNA can also be cleaved by endonuclease at either sequence 
specific or sequence non-specific sites. The resulting products can be degraded 
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either by Xrn1 from 5’ to 3’, or by exosome from 3’ to 5’ direction (Dodson & 
Shapiro, 2002). This mRNA decay process is independent of deadenylation. RNA 
interference (RNAi), a hot research field in recent years, belongs to this category 
of mRNA turnover. RNAi is a conserved biological process response to sequence-
specific double-stranded RNA (dsRNA), leading to efficient target gene silencing 
(Fire et al, 1998). Double stranded RNA homologous to specific endogenous 
mRNA is firstly cut by an RNaseIII family enzyme Dicer to form short interfering 
RNA (siRNA), which is 21-22 nucleotide long with two-nucleotide 3’ overhangs 
(Elbashir et al, 2001). Some noncoding regulatory RNAs (miRNA) can also 
trigger RNAi in a very similar pattern (Bernstein et al, 2001). RNA-induced 
silencing Complexes (RISC) are then assembled, each containing a single-   
 
 
Parker and Song, Nat. Stru. & Mol Bio. (2004) 11, p121 
Fig 2. Eukaryotic mRNA decay pathways: General and special mRNA decay 
pathways from both directions are indicated. 
 
 
stranded version of siRNA or miRNA and other protein components (Bartel, 
2004). RISC are primed for the target mRNA via these small RNAs, after which 
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the “Slicer”----an Argonaute protein cleaves the target mRNA, thereby leading to 
its further degradation by exonucleases (Bartel, 2004). 
 
1.1.3 Specialized mRNA decay pathways 
Eukaryotic cells have evolved quality control mechanisms to monitor mRNA 
synthesis. There are several specialized mRNA decay pathways that function to 
eliminate aberrant mRNA, which is harmful to the cells. Abnormal mRNA 
transcripts with premature stop codon (PTC) can be recognized and degraded by a 
process called nonsense-mediated decay (NMD) (Wagner & Lykke-Andersen, 
2002). Similarly, aberrant mRNA transcripts without a stop codon can be 
degraded by a nonstop decay (NSD) process (Frischmeyer et al, 2002) (Fig 2). 
These mRNA decay pathways are also deadenylation-independent. While the 
NSD pathway solely requires the exosome-mediated 3’ to 5’ degradation 
process(van Hoof et al, 2002), the NMD pathway is more complicated. It can 
occur from both the 5' end of mRNA (involving decapping and 5'-to-3' 
exonucleolytic digestion by Xrn1) or the 3' end (through accelerated 
deadenylation and exosome-mediated 3'-to-5' decay) (Lejeune et al, 2003; 
Mitchell & Tollervey, 2003). More recently, it has been reported that in 
Drosophila, NMD is initiated by endonucleolytic cleavage in the vicinity of the 
nonsense codon. The resulting 5' fragment is rapidly degraded by exonucleolytic 
digestion by the exosome, whereas the 3' fragment is degraded by Xrn1(Gatfield 
& Izaurralde, 2004). 
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About 30% of inherited genetic disorders, including osteogenesis imperfacta, 
Stickler’s syndrome and Marfan mutations, are caused by premature termination 
codon (PTC) (Frischmeyer et al, 2002). These aberrant transcripts result in 
truncated proteins with dominant negative activities. Nonsense-mediated mRNA 
decay (NMD) eliminates these PTC-containing mRNAs, thus preventing 
formation of the aberrant protein products (Baker & Parker, 2004). Three trans-
acting factors, Upf1, Upf2, and Upf3, form a ‘surveillance’ complex and are 
essential to the NMD pathway (Cui et al, 1995). Upf proteins are conserved 
throughout all eukaryotes and play roles both in mRNA translation and NMD 
(Wilkinson, 2005). In S. cerevisiae, a cis-acting element downstream of the 
nonsense codon (DSE) is required for the recognition of PTC-containing mRNA 
(Baker & Parker, 2004). While in mammals, PTC recognition depends on its 
position relative to the last exon-exon junction (EJC).  mRNA that contains a 
nonsense codon more than ~50 nucleotides upstream of the last exon-exon 
junction will be subjected to  NMD (Lejeune & Maquat, 2005).  The Upf complex 
associates with the translation release factor eRF3. After translation termination, 
this complex scans the downstream sequence, DSE (in yeast) or EJC (in mammals) 
are signals for premature translation termination and will trigger rapid, 
deadenylation-independent mRNA decay (Conti & Izaurralde, 2005). 
Recently, it has been reported that in addition to eliminating aberrant mRNAs 
containing PTCs, NMD is also implicated in regulating the expression of normal 
transcripts (Hillman RT et al, 2004). Depletion of key protein for NMD Upf1 in 
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Table1. Enzymes involved in eukaryotic mRNA decay 
 
Protein  Function  Features 
Deadenylation related  
Ccr4 Catalytic subunit of the 
deadenylase 
Homology to Mg2+ dependent 
endonucleases 
Pop2 Regulator of 
deadenylation, may also 
have deadenylase activity 
Homology to RNaseD 
 
Pan2/Pan3 Minor deadenylases, 
required for poly(A) 
length control 
Pan2 has homology to RNaseD 
PARN Mammalian deadenylase 
 
Homology to RNaseD. Can bind 
to 5' cap, which stimulates 
deadenylase activity 
Decapping related  




Dcp2 Catalytic subunit of 
decapping holoenzyme 
NUDIX motif, conserved Box A 
and Box B motif 
DcpS Hydrolyze residual cap 
structure in 3’-5’ pathway 
HIT motif, functions as 
homodimer  
X29 removes the m7G and 
m227G caps from nuclear 
U8 snoRNAs 
A NUDIX hydrolase, nucleotide 
diphosphatase 
Exonucleases 
Xrn1 Major cytoplasmic 5'- 3' 
exonuclease 
Shares sequence motifs with other 
Mg2+-dependent 5’-3’ 
exonuclease 




Core complex of 3'-5' 
exonucleases termed the 
exosome 
A complex of 3'-5' exonucleases 
termed the exosome 
Rrp44 Additional exosome 
subunit 
Related to RNaseD family 
members 





Both yeast (He F et al, 2003) and mammalian cells (Mendell JT et al, 2004) 
altered the global expression transcriptome.  
In contrast to NMD, nonstop decay proceeds from 3’ to 5’ and depends on the 
exosome instead of the Upf complex. When the ribosome reaches the 3’ end of 
the transcript without a stop codon, the cytoplasmic adaptor protein Ski7p, which 
resembles translation elongation and termination factors, will bind to the empty 
ribosomal A site and recruits exosome to rapidly degrade the transcript from the 
3’ end (Van Hoof A et al, 2002). 
Proteins involved in the eukaryotic mRNA decay are summarized in Table1. 
 
1.2 Decapping process 
 
1.2.1 Decapping process in 5’-3’ decay pathways 
Since the majority of the mRNAs in yeast are degraded from 5’ to 3’( Parker 
& Song, 2004) , most of the early knowledge about decapping process in the 5’ to 
3’ pathway comes from S. cerevisae. It has been shown that poly(A)-binding 
protein (Pab1p) is an inhibitor of decapping (Caponigro & Parker, 1995). In 
addition to binding to the poly(A) tail, Pab1p can also interact with eIF4G, a 
component of the cap-binding complex eIF4F. Thus mRNA forms a close-loop 
structure through these interactions and is protected from the access of decapping 
enzymes (Decker & Parker, 1993). After deadenylation Pab1p dissociates, the 
translation machinery also dissociates from the cap structure, allowing the binding 
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of the decapping enzymes. This transition drives the mRNA to exit from 
translation status and targets it for degradation. 
 The subsequent decapping process occurs in specific cytoplasmic structures 
called P (process) bodies. Proteins involved in mRNA decapping and 5’ to 3’ 
exonucleolytic decay are found in these specific P bodies. For example, GFP 
tagged Dcp1p, Dcp2p, Lsm1p, Pat1p, Dhh1p, and Xrn1p (all of these proteins are 
component of decapping machinery) have been shown to localize in P bodies in 
yeast (Sheth & Parker, 2003). These P bodies are highly dynamic. Their sizes and 
numbers are correlated with the amount of mRNA in the decapping process. 
Intermediates of decapping have also been found to localize in the P bodies 
(Sheth & Parker, 2003). After an mRNA targeted for decay has been sequestered 
in these special cytoplasmic foci, different proteins assembled on the mRNA to 
form distinct decapping complexes and enhance the decapping enzyme activity. 
As shown in Fig 3b, the general mRNA decay requires a complex containing 
Lsm1 to Lsm7 protein complex (RNA-binding complex), Pat1p (unknown 
function), Dhh1p (DEAD box ATPase), Edc1-3 proteins (enhancers of decapping) 
and Dcp1p/Dcp2p (Coller & Parker, 2004). In the 5’ to 3’ NMD pathway, the 
decapping complex contains Upf1p, Upf2p and Upf3p, which recruit the 
decapping enzyme Dcp1p/Dcp2p (He & Jacobson, 1995). One special decapping 
complex forms on the RPS28a mRNA. The RPS28a protein binds to its own 
mRNA at a stem-loop structure in the 3’-UTR and interacts with the Edc3 protein, 
which recruits Dcp1p/Dcp2p (Kshirsagar & Parker, 2004). 
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Recently, an additional decapping activity has been reported in the Xenopus 
nucleus. The protein X29, which contains a similar NUDIX domain to Dcp2, has 
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Fig 3. Eukaryotic decapping enzymes: (a) mRNA decapping enzymes and their 
substrates. (b) different decapping complexes on different mRNA substrates. 
 
1.2.3 Decapping process in 3’-5’ decay pathways 
It has been well established that mRNA is predominantly degraded in 5’-3’ 
direction in yeast. Recent studies have demonstrated that the 3’ to 5’ decay 
pathway is the major pathway in mammalian cells both in vitro and in vivo (Wang 
& Kiledjian, 2001). After degradation of mRNA body from 3’ to 5’ by exosome, 
the residual cap structure was eliminated by the enzyme DcpS (Fig 3a, see below). 
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1.3 Decapping Enzymes 
 
1.3.1 Dcp1/Dcp2 complex 
In S. cerevisiae, Dcp1p and Dcp2p form a complex to hydrolyze the cap 
structure in the 5’ to 3’ mRNA decay pathway (Coller & Parker, 2004). These two 
proteins interact both in vitro and in vivo (Fischer & Weis, 2002). Deletion or 
mutation of either protein results in the reduction of the decapping activity 
(Dunckley & Parker, 1999). Recombinant Dcp2p protein expressed from E. coli 
has low decapping activity, which is enhanced by Dcp1p (Steiger et al, 2003). 
Although Dcp2 protein in S. pombe and mammals has strong decapping activity 
by itself, mammalian Dcp2 protein colocalizes and copurifies with Dcp1 protein 
(Lykke-Andersen, 2002). Dcp2 protein contains a highly conserved Nudix motif, 
which has been found in a class of pyrophosphatases that hydrolyze a nucleotide 
diphosphate linked to moiety X (Nudix). The Nudix motif is critical for the 
function of Dcp2 since mutations in the Nudix motif abolish the decapping 
activity (Dunckley & Parker, 1999; Wang et al, 2002). Dcp2 is required for both 
deadenylation-dependent and deadenylation-independent (NMD) 5’ to 3’ mRNA 
decay. Activity of Dcp2 is specific to N7-methylated guanosine cap. Cap cleavage 
by Dcp2 generates an m7GDP and a 5’-monophosphorylated mRNA fragment 
(pRNA). Like other Nudix domain proteins, Dcp2 requires various divalent 
cations as cofactors for efficient decapping activity, preferentially Manganese 
(Dunckley & Parker, 1999). Interestingly, the activity of Dcp2 is not inhibited by 
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the cap structure. Instead it can be inhibited by uncapped mRNA, which suggests 
that hDcp2 is a RNA-binding protein and the RNA binding is essential for its cap 
binding and hydrolysis (Piccirillo et al, 2003). The activity of Dcp2 requires a 
substrate with a length more than 25nucleotides. The preference for long mRNA 
is biologically significant since it prevents the decapping of mRNAs in active 
translation status (van Dijk et al, 2002). 
Dcp1 protein is also conserved in eukaryotes. It was previously reported that 
Dcp1 has decapping activity (LaGrandeur & Parker, 1998). However, recent 
studies have shown that Dcp1 alone does not have decapping activity (She et al, 
2004). In S. cerevisiae, Dcp1p and Dcp2p function together as a holoenzyme. 
Human Dcp1 protein has two homologs, Dcp1a and Dcp1b. hDcp1a and hDcp2 
copurify with decapping activity and form a complex in human cell extracts 
(Lykke-Andersen, 2002) . Dcp1a (also called SMIF) may also play a role in 
SMAD-mediated TGF- signaling pathway(Callebaut, 2002). Recently, a high-
resolution X-ray structure of yeast Dcp1p protein has been solved (She et al, 
2004). Dcp1 belongs to a class of EVH1/WH1 domain proteins. EVH1 domains 
are protein-protein interaction modules that interact with various substrates 
containing proline-rich sequence (PRS). Sequence comparisons reveal that Dcp1p 
belongs to a novel class of EVH1 domain proteins. Mapping on the molecular 
surface reveals two conserved patches. One is responsive for binding to PRS-
containing target and the other is critical for its function. Another hydrophobic  
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Table2. Components and Regulators for decapping complex in yeast 
 
Protein Properties Effects on decapping 
Pab1p 
 
Major protein associated 
with polyA tail. 
Blocks mRNA decapping and 
stimulates translation. Primary coupler 





Component of the eukaryotic 
translational initiation complex eIF-4F. 
Blocks mRNA decapping by competing 





Forms a heteroheptameric ring complex 
and interacts with the mRNA after 
deadenylation. May facilitate the 
assembly of the decapping complex. 
Pat1p 
 




Interacts with both polyadenylated and 
deadenylated transcripts. Required for 
efficiency of both decapping and 
formation of P bodies in vivo. May 




Member of the ATP-
dependent DExD/H box 
helicase family 
 
Required for the efficiency of 
decapping in vivo. Homologs across 
species are required for translational 




Small, basic proteins 
with weak homology to 
each other 
Required for efficient decapping in 




A general and mRNA-
specific regulator of 
decapping. 
Regulates the decapping of the RPS28a 
mRNA. Recruits dcp1p/dcp2p complex 
Upf1p, Upf2p, 
Upf3p 
Upf1p is an ATP-
dependent RNA helicase 




patch was also mapped and mutation in this patch disrupted decapping activity 
(She et al, 2004).  
The exact function of Dcp1 in decapping is still unclear. Dcp1 can interact 
with Dcp2 both in vitro and in vivo. Immunomicroscopy studies show that Dcp1 
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co-localizes with Dcp2 in the cytoplasmic P bodies. In addition, recombinant 
Dcp1p can enhance the activity of Dcp2p (Sheth U and Parker R, 2003).  All 
these results suggest that Dcp2p is the catalytic subunit and Dcp1p enhances its 
activity (She et al, 2004) .  
Proteins involved in the composition or regulation of 5’ to 3’ decapping 
complex of S .cerevisae are summarized in Table2. 
 
1.3.2 Scavenger Decapping Enzyme DcpS 
A scavenger decapping activity for short cap structures in eukaryotes has been 
reported about 30 years ago (Nuss et al, 1975; Nuss & Furuichi, 1977). However, 
the corresponding enzyme had not been identified until recently. This “scavenger” 
enzyme, DcpS, is required for elimination of the m7GpppN cap oligo-nucleotide 
following the 3’ to 5’ mRNA degradation by exosome (Liu et al, 2002). 
Consistent with this role, it has been shown that DcpS associates with a subset of 
exosome proteins in vivo (Wang et al, 2001), suggesting that DcpS may affect the 
activity of exosome complex in the mRNA decay process. Moreover, cap analogs 
can compete with intact mRNAs for cap binding protein eIF4E and interfere with 
their translation initiation (Gao et al, 2000). On the other hand, it has also been 
shown that cap analogs inhibit deadenylation activity, the initial step of general 
mRNA decay pathways (Dehlin et al, 2000). Therefore, by elimination residual 
cap structure DcpS may have dual functions in regulating both deadenylation and 
translation. DcpS functions in distinct mRNA decay pathways from Dcp1/Dcp2 
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proteins, including the deadenylation-dependent general 3’ to 5’ mRNA decay, 
ARE-induced mRNA decay, 3’ to 5’ NMD, and 3’ to 5’ NSD. DcpS also creates 
different products compared to Dcp2 (Liu et al, 2002). DcpS cleaves the cap 
structure at a different phosphate bond and generates an m7G monophosphate 
(m7GMP) and an oligo nucleotide with a diphosphate terminal.  
 
1.4 Biochemical and Structural Characteristic of DcpS 
 
1.4.1 Biochemical characteristic of DcpS 
The DcpS protein is highly conserved throughout eukaryotes and DcpS from 
different organisms have similar decapping activities. Human DcpS is a 39 KDa 
protein and belongs to the histidine triad (HIT) protein family. HIT proteins are a 
superfamily of pyrophosphatases that share a motif comprised of His--His--
His-, where  is a hydrophobic amino acid. The central histidine of a HIT motif 
is critical for the pyrophosphatase activity. It was proposed that HIT proteins 
could function as regulators of dinucleotide (NpppN) signaling molecules 
(Brenner et al, 1999). However, their exact biological roles were unclear. DcpS is 
the first HIT protein whose biological function has been defined. In addition, the 
HIT motif of human DcpS is essential for its decapping activity. Mutation of the 
central histidine in the HIT motif to asparagine abolishes the decapping activity of 
DcpS (Liu et al, 2002).  
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DcpS has a substrate specificity for N7 methylated guanosine that is linked to 
<10nt oligo nucleotide through a 5’-5’ tri-phosphate bridge. This specificity is 
biologically significant. It prevents pre-mature decapping of mRNAs which are 
not targeted for decay by DcpS. Thus DcpS must be capable of distinguishing 
between capped long mRNAs and residual cap structures derived from the mRNA 
decay processes. Interestingly, although DcpS has an extremely low decapping 
activity for capped long mRNA (2500 fold lower than that for the cap analog 
m7GpppG), it can bind to the cap structure of long mRNA with a reasonable 
affinity only 17 fold lower than that for the cap analog (Liu et al, 2004). In 
addition, a competition experiment demonstrates that DcpS can efficiently 
compete with eIF4E for binding to cap structures but not to long mRNAs, which 
may further prevent DcpS accessing long mRNAs in vivo (Liu et al, 2004). The 
low affinity for long mRNAs and high affinity for cap structures are consistent 
with the function of DcpS. On one hand, it prevents DcpS interfering with normal 
mRNA translation initiation. On the other hand, it also prevents the occupation of 
eIF4E by cap structures.  
Interestingly, DcpS was also found to act in the 5’-3’ mRNA decay pathway 
in addition to the 3’-5’ pathway by converting m7GDP, a product released by 
Dcp2, to m7GMP, thereby preventing mis-incorporation of methylated nucleotides 
into nucleic acids (van Dijk et al, 2003).  Further evidence supporting the role of 
DcpS in the 5’-3’ mRNA decay comes from the observation that DcpS is 
susceptible to m7GDP competition (Liu et al, 2002).  
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The scavenger decapping process by DcpS occurs in the cytoplasm. However, 
recent immunofluorescent study revealed that hDcpS is predominantly a nuclear 
protein, although it is also localized in the cytoplasm (Liu et al, 2004). Similar 
results also came from studies in S. pombe (Salehi et al, 2002) and monkey cells 
(Kwasnicka et al, 2003).  The nuclear function of DcpS is currently unclear. It 
may be responsible for decapping nuclear aberrant transcripts. 
Recent structural study on human DcpS has shown that DcpS is a modular 
protein consisting of an N-terminal domain and a C-terminal domain(Gu et al, 
2004). While the C-terminal domain contains the HIT motif that is essential for 
the enzyme activity, the N-terminal domain is indispensable for the decapping 
process and facilitates cap structure binding (Liu et al, 2004) .  
DcpS proteins are highly conserved among different species. Studies of DcpS 
proteins in other species reveal some interesting results. S. cerevisiae has two 
highly homologous proteins, but only one of them has the decapping activity. It 
has been shown that the difference in the N-terminal domain is critical for the 
difference in function (Liu et al, 2004) . The DcpS homolog in S. pombe, also 
called Nhm1, is purified as a cap binding protein. Nhm1 interacts with both RNA 
and oligo-nucleotide. In addition, it inhibits mRNA translation in vitro. It was 
reported that Nhm1 could decap long mRNA substrate and release the m7GMP 
(Salehi et al, 2002). This functional difference is difficult to explain since Nhm1 
is highly homologous to human DcpS. In C. elegans, the majority of mRNAs are 
modified by an N2, 2, 7-trimethylated Guanosine cap, and C. elegans DcpS has 
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distinct activity on single-methylated and triple-methylated cap structure (Cohen 
et al, 2004), suggesting that the DcpS protein in C. elegans has a distinct 
mechanism to accommodate this cap structure. 
 
1.4.2 Structural characteristic of DcpS and related proteins 
Before the identification of DcpS, three-dimensional structures of several HIT 
proteins have been solved. For example, the crystal structure of histidine triad 
nucleotide-binding protein (HINT) forms a homodimer structure and each 
monomer can bind to a ligand. HINT structures in complex with different 
nucleotides revealed that the conserved HIT motif is involved in ligand binding 
(Brenner et al, 1997; van Dijk et al, 2002; van Dijk et al, 2002). The structure of 
protein kinase C interacting protein 1 (PKCI-1) is very similar to that of HINT 
protein (Lima et al, 1996). The fragile histidine triad (FHIT) protein represents 
another branch of HIT superfamily. It is a diadenosine triphosphate (ApppA) 
hydrolase reported as a potential tumor suppressor. The crystal structure of FHIT 
apo-protein and FHIT in complex with ligand revealed similar homodimer 
structures, and the HIT motif of FHIT is also involved in ligand binding(Pace et 
al, 1998).  
These structural analysis indicate that HIT proteins exist as homodimers 
through formation of a continuous 10-stranded antiparallel β sheet, with each 
protomer containing an active site and a nucleotide binding pocket that 
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coordinates the pyrophosphate bond with respect to the three histidines of the 
catalytic HIT motif. No evidence for metal-ion binding has been found either in  
 
 
Lima et al. Structure (1997) 5: 763-774 
Fig 4. Comparison of the structures of GalT, PKCI and FHIT: (a) Ribbon 
diagrams of GalT, PKCI and FHIT. Note the similar overall fold between these 
structures. Histidine residues involved in catalysis are shown in red. (b) Close-up 
of the active-site regions of GalT, PKCI and FHIT. Only a subset of residues in 
the active site is depicted. 
solution or in crystal structures (Brenner et al, 1997; Brenner et al, 1999; Lima et 
al, 1997; Pace et al, 1998). Interestingly, the structure of Galactose-1-phosphate 
uridyltransferase (GalT) contains two sequentially fused HINT protomer 
structures and conserves the quaternary structure of HINT dimer although they 
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share no overall sequence homology. This indicated a common evolutionary 
origin (Brenner et al, 1997). The structures of GalT, PKCI and FHIT are 
compared in Fig 4. The GalT monomer has only one active-site histidine located 
on the right side of Gal T in the diagram, while HIT dimers of HINT and FHIT 
have two equivalent active sites (Fig 4a). In addition to the conservation of 
overall structural folding and the most important histidine, several hydrophobic 
residues that make contact to the nucleoside base are also conserved (Fig 4b). 
Consistent with those previous studies indicating that HIT proteins form 
homodimers, The preliminary study presented in this thesis also suggests that 
human DcpS exists as a dimer. However, other known HIT proteins share no 
sequence homology with DcpS except for the HIT hexapeptide. Thus human 
DcpS and its homologs in other species could possibly have a different structure 
from other HIT proteins and may represent a new branch within this superfamily.   
More recently, the crystal structures of human DcpS, with the active site 
His277 mutated to asparagine, in complex with either m7GpppG or m7GpppA 
have been determined (Gu et al, 2004). The structures show that DcpS with bound 
cap analogue forms an asymmetric dimer structure. It simultaneously creates an 
open nonproductive DcpS-cap complex and a closed productive DcpS-cap 
complex, which alternate via 30Å domain movements. Combined with 
mutagenesis and biochemical analysis, an autoregulatory mechanism has been 
proposed, in which premature mRNA decapping is avoided by blocking the 
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conformational changes that are required to form a closed productive active site 
capable of hydrolyzing the cap structure.  
 
1.5 Aims of project 
Structural and functional analysis of proteins involved in the mRNA decay is 
a major research field in our lab. Both Dcp1p and Dcp2 structures were solved in 
our lab and other related projects are in progress. DcpS plays an essential role in 
the 3’ to 5’ mRNA decay. Solving the three dimensional structure of DcpS (apo-
protein and in complex with ligand) by X-ray crystallography will provide an 
insight into the molecular basis for the mechanism of the scavenger decapping. 
Specifically, it will lead to understanding the specificity of DcpS for methylated 
oligo-nucleotide substrates and give clues to its potential regulatory roles in 
mRNA turnover. 
During the process of this project, structures of mutated human DcpS in 
complex with cap analogs were published, which revealed asymmetric structures 
upon substrate binding. However, there are still unsolved issues with respect to 
this structure and its functional mechanism. Does the mutation of key amino acid 
affect the protein structure or its interaction with its substrate analogs? Is the 
asymmetry structure also present in the ligand-free protein? Does substrate 
binding cause a conformation change in the enzyme? If so, what kind of change? 
Is m7GDP a substrate or inhibitor for DcpS? How to explain its substrate 
specificity for residual cap structures? 
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To solve all these issues and to gain more insight into the molecular 
mechanism of scavenger decapping by DcpS, we have determined the crystal 
structures of human DcpS in ligand-free form (apo-DcpS) and in complex with 
m7GDP. Structural comparison combined with mutagenesis suggests a dynamic 

















2. MATERIAL AND METHOD 
 
2.1 Protein expression and purification 
The full-length human DcpS (amino acid 1-337, 1014bp) gene was cloned 
from human cDNA library Marathon-ReadyTM (CLONTECH) by PCR 
amplification using oligo-nucleotide primers DcpS-F 
(GCGCGGCGGATCCATGGCGGACGCAGCTCCTCAAC) and DcpS-R 
(GGCCGCTCGAGTTAGCTTTGCTGAGCCTCCTGCAAG). The DNA 
fragment from PCR reaction was digested with restriction enzyme BamH1 and 
Xho1 and ligated into the same site of pGEX-6p-1 vector (Pharmacia Biotech) 
and transformed into E. coli. Strain BL21 (DE3) star (Novagen). Cells harboring 
the GST-DcpS expression vector were grown in LB medium at 310K until A600 
reached to 0.5-0.7. Protein expression was induced by 0.1mM IPTG at 291K for 
16 hours. Four liters of such cell culture were used for recombinant GST-DcpS 
purification. Cells were harvested and lysed by incubation with lysozyme in lysis 
buffer ( 20mM Tris-HCl, pH7.6, 500mM NaCl, 2mM DTT, 1mM EDTA, 0.1mM 
PMSF, 2mM Benzamide) followed by sonication. Supernatant and pellet of cell 
lysate were separated by centrifugation (Beckman) at a speed of 18,000 rpm for 
one hour. The clarified supernatant was then loaded onto a glutathione-Sepharose 
4B column (Amersham) at a loading speed of 0.5 ml/min. After loading finished, 
column was washed with lysis buffer for about 10 column volumes to eliminate 
non-specific binding proteins. GST-fusion protein was eluted by 50 mM reduced 
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glutathione (Sigma) in lysis buffer with pH adjusted to 8.0. GST-DcpS fusion 
protein was then cleaved by PreScission protease (Amersham) overnight at 277K. 
Glutathione was eliminated by passing a desalting column (Amersham). Cleaved 
protein was reloaded onto a glutathione-Sepharose 4B column again. GST and 
proteins associated with GST bound back to the column and flowthrough 
fractions containing DcpS was collected (Fig 5a). DcpS was further purified by 
MonoQTM (Amersham) anion exchange column, with  loading buffer A (20mM 
Tris-HCl, pH8.0, 100mM NaCl, 2mM DTT, 1mM EDTA, 0.1mM PMSF, 2mM 
Benzamide) and final elution buffer B (20mM Tris-HCl, pH8.0, 1000mM NaCl, 
2mM DTT, 1mM EDTA, 0.1mM PMSF, 2mM Benzamide). DcpS was eluted out 
at gradient around 15% of the buffer B (Fig 5b, 5c). Fractions B5 and B6 
containing DcpS were then load on a Hiload 20/60 superdex75 (Amersham) gel 
filtration column. The peak corresponding to DcpS comes out at an elution 
volume of about 130 ml, corresponding to a molecule weight of 80 kDa (Fig 5d). 
SDS-PAGE showed that DcpS protein is >95% pure (Fig 5e), with an 
approximate molecular weight of 39 kDa. Gel filtration result indicated that DcpS 
has a dimeric quaternary structure which is consistent with other HIT proteins. 
Protein identity was confirmed by N-terminal sequencing (DBS facility, NUS) 
and Mass spectrometry (IMCB facility).  
Although the structures of DcpS were determined by molecular replacement 
method eventually, there is no homologous model available at beginning of this 




















Fig 5: Expression pattern of human DcpS: (a) DcpS purified by GST affinity 
columns. lane1: cell lysate before IPTG induction, lane2: cell lysate after 
induction, lane3: loading supernatant sample, lane4: flowthrough, lane5: wash of 
nonspecific binding, lane6: eluted GST-fusion protein, lane7: protease treated 
sample, lane8: samples after second GST column. (b) Purification pattern of 
MonoQ (c) SDS-PAGE result after MonoQ. lane1-3 corresponding to B5-B7 in 
(b), lane4-6: B9-B11, lane7-8: C2-C3. (d) Purification pattern of gel-filtration. (e) 
SDS-PAGE result after gel-filtration.lane1-7 corresponding to D4-D10 in (d). 






















There are only two methionines (including the first amino acid) in the 337 amino 
acids of full length DcpS protein, which is not enough for MAD or SAD phasing 
method. To incorporate enough Se atoms for MAD analysis, two Leucine 
(Leu206 and Leu317) to Methionine mutations were introduced by 
QuickChange® Site-Directed Mutagenesis kit (STRATAGENE). SeMet-
substituted mutant DcpS protein was expressed and purified in the same protocol 
as that used for wild type protein except that the DTT concentration was 10 mM. 
The double mutant protein DcpS was used for decapping assay and showed a 
similar activity to the wide-type DcpS protein. 
 
2.2 Crystallization methods and conditions 
Purified DcpS protein was concentrated to 10 mg/ml and used for 
crystallization screening. Initial crystallization conditions were screened at 293 K 
by the hanging-drop vapor diffusion method using commercial Crystal Screening 
kits (48x6, Hampton Research and Emerald Biostructures). Equal volume (1l) of 
protein and crystallization buffer were mixed and equilibrated against 300l of the 
well solution. Small and clustered crystals were obtained from a condition 
consisting of 20% (w/v) PEG8000, 0.05M KH2PO4 (Fig 6a). Optimization of 
crystallization condition by commercial additive screening kits (24x3, from 
Hampton Research) failed to give single crystal. By reducing protein 
concentration to 2 mg/ml, micro-seeding technique and adding glycerol into the 
initial condition, single plate-like crystal was obtained. But the crystal size was 
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too small for X-ray diffraction (Fig 6b). By optimizing the condition and macro-
seeding technique, single crystals with a dimension of 0.5mmx0.2mmx0.02mm 
were obtained (Fig 6c) using a reservoir solution consisting of 25% PEG3350, 
0.1M KH2PO4, 0.05M NaCl and 13% Glycerol and a same drop solution except 
for 26% glycerol. Native, double-mutant and SeMet substituted Dcps proteins 
were crystallized at similar conditions and have similar crystal morphology. 
For DcpS in complex with cap analogs m7GDP, screening failed to give any 
crystals. So the crystal of apo-DcpS was soaked in cry-buffer containing 5mM 
m
7GDP for 12 hours before flash frozen by liquid nitrogen. 
 
 
(a)                                              (b)                                         (c) 
 
Fig 6. Crystals of human DcpS protein: (a) Initial auto-grow crystals from 
commercial screening kit which is small and clustered. (b) Single plate-like 
crystals after micro-seeding. (c) Single crystal after macro-seeding, the final size 
is about 0.5mmx0.2mmx0.02mm 
 
2.3 Data Collection and reduction 
Crystals are mounted on nylon cryoloops (Hampton Research). Mother liquor 
(25% PEG3350, 0.1M KH2PO4, 0.05M NaCl, 13% Glycerol) was used as 
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cryoprotectant directly. Crystals were then flash-cooled in liquid nitrogen. Two 
sets of diffraction data were collected. One data set of DcpS in complex with 
m7GDP (crystal presoaked in m7GDP containing buffer) was collected at 
beamline BL42B at Spring-8 (Hyogo, Japan). A single native crystal was used to 
collect a data set at a wavelength 0.9997 Å. Data were collected with a crystal-to-
detector distance of 250 mm, an oscillation range of 1° and an exposure time of 
30s per frame. Data indexing and integration were performed with Mosflm (Leslie, 
1990) and SCALA (CCP4, 1994). A SAD data set was collected using a double-
mutated SeMet derivate DcpS (designated as apo-DcpS below) crystal at 
wavelength of 0.93Å on beamline BM14UK at ESRF (Grenoble, France) using a 
MarCCD detector. This data set was kindly collected and processed using HKL 
software package (Otwinowski, Z & Minor, W, 1997) by Dr. Martin A. Walsh in 
ESRF, France. 
The resolution limits for data reduction were selected on the basis of 
completeness and signal-to-noise ratio and set to 2.0 Å for the apo-DcpS and 2.5 
Å DcpS-m7GDP data sets, respectively. Notably, there are two different crystal 
forms, each having the same crystal morphology. Both forms belong to the 
orthorhombic system. Crystals of DcpS-m7GDP belong to space group P212121, 
with cell parameters a=100.93Å, b=105.14Å, and c=138.65Å while crystals of 
apo-DcpS belong to space group P21212 with cell parameters a=101.92Å, 
b=103.86Å, and c=71.07Å. As shown in the Table 3, space group P212121 for 
native crystal and P21212 for SeMet derivative were also observed. Thus these 
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different crystal forms were not caused by Leu to Met mutation or SeMet 
substitutions , presumably caused by the binding of m7GDP to DcpS. 
Calculation of VM (Matthews, 1968) gave a typical value of 2.25 Å3 Da-1 and 
a solvent content of 44.95% for apo-DcpS, corresponding to two molecules per 
asymmetric unit. For crystals of DcpS- m7GDP, VM is of 2.35 Å3 Da-1 and solvent 
content is calculated to be 47.31%. These values correspond to the presence of 
four molecules per asymmetric unit. 
 
2.4 Structure determination 
The structure of the m7GDP-DcpS complex was solved by molecular 
replacement method with Molrep (Vagin & Teplyakov, 1997) using the 
coordinates of the m7GpppG-DcpS complex as the search model (Gu et al, 2004). 
The results from Molrep clearly showed a solution with R-facto of 0.484 and 
correlation coefficient of 0.527. Manual model rebuilding was carried out with 
program O (Jones et al, 1991). Difference Fourier maps clearly showed the bound 
nucleotides (Figure 9d). The electron densities for two of the m7GDP molecules 
are well defined while the β-phosphates are disordered for the other two m7GDP 
molecules, thus these two m7GDP molecules are modeled as m7GMP. Topology 
and parameter files for m7GDP and m7GMP was generated with the help of HIC-
UP server (Hetero-compound Information Centre - Uppsala) (Kleywegt, G.J. and 
Jones, T.A.1998). Crystallographic refinement was carried out using CNS 
(Brunger et al, 1998). The final round of refinement was done by REFMAC5 
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(Murshudov et al, 1997). This structure was refined to a final Rwork=21.3 %, 
Rfree=26.7%, with 89.2% of the residues located in the most favored regions in the  
Ramachandron Plot (Table 3, Fig 7).  In the structure of m7GDP-DcpS, residues 
1-39, 69-77, 111, 337 for chain A, residues 1-39, 70-78, 337 for chain B, residues 
1-38, 68-76, 337 for chain C, and residues 1-37, 71-74, 99-101, 110 for chain D 
are assumed to be disordered as interpretable electron densities are not observed 
for these regions.  
The apo-DcpS data set is collected using a Semet deriviated crystal. Semet 
could be useful for additional unbiased phases, but molecular replacement method 
was used in our case. The C-terminal domain (containing amino acids A146-336, 
B146-336) of m7GDP-DcpS structure was then used as a search model for apo-
DcpS structure.. Molrep gave a solution with R-factor of 49.9%, correlation 
coefficient of 0.495. The whole structure of DcpS- m7GDP was also used as 
search model. However, the electron densities for the N-terminal domain showed 
significant difference from the model, suggesting a dramatic conformation change 
of N-terminal domain with respect to the C-terminal domain. Part of the N-
terminal domain was built by Arp/wArp (Perrakis et al, 1999). About 50 out of 
200 amino acids were built automatically. The rest of the N-terminal domain was 
built manually using O (Jones et al, 1991). The model was refined by CNS 
(Brunger et al, 1998) and REFMAC5 (Murshudov et al, 1997) to a final 
Rwork=22.0%, Rfree=25.3%, with 90.5% of the residues located in the most favored 
regions of the Ramachandron Plot (Table 3, Fig 8).  In the structure of apo-DcpS,   
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Fig 7. Ramachandron Plot for structure of DcpS-m7GDP 
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Fig 8. Ramachandron Plot for structure of apo-DcpS 
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residues 1-39, 71-76, 286-293 and 337 for protomer A, and residues 1-39, 70-77, 
286-292 and 337 for protomer B were not modeled as these regions are not visible 
in the electron density map and are assumed to be disordered. Statistics of 
structure determination and refinement are summarized in Table 3.  
Table 3. Data collection and Refinement statistics 
 apo-DcpS a m7GDP-DcpS complex 
Data Collection 
Wavelength (Å) 0.93 0.9997 
Space Group  P21212 P212121 
Unit cell dimensions 
a (Å) 101.92 101.93 
b (Å) 103.86 105.14 
c (Å) 71.07 138.65 
Resolution Range(Å) 50.0-2.0 32.0-2.5 
Unique Reflections 51,633 51,097 
Completeness (%) 100 (99.8) 98.9 (98.9) 
Rmerge b (%) 7.0 (40.0) 8.7 (26.0) 
I/ 22.3 (2.5) 7.5 (2.8) 
Refinement 
Total atoms 5177 10,112 
Resolution Range(Å) 20.0-2.0 20.0-2.5 
Rwork c (%) 22.0 21.3 
Rfree d (%) 25.3 26.7 
R.m.s deviations from ideal values 
Bond Length (Å) 0.009 0.009 
Bond Angle  (°) 1.14 1.34 
Ramachandron Plot    
Most favored regions (%) 90.5 89.2 
Disallowed regions (%)        0.4 0.1 
 
Values in parentheses indicate the specific values in the highest resolution shell 
aThe apo-DcpS structure was refined against a dataset collected from a SeMet-
containing crystal. 
bRmerge = |Ij-<I>|/Ij, where Ij is the intensity of an individual reflection, and <I> is 
the average intensity of that reflection. 
cRwork = ||Fo| - |Fc||/|Fc|, where Fo denotes the observed structure factor amplitude, 
and Fc denotes the structure factor amplitude calculated from the model. 
dRfree is as for Rwork but calculated with 5.0% of randomly chosen reflections omitted 
from the refinement. 
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2.5 Assay of Decapping Activity 
RNA was in vitro transcribed by AmpliScribeTM SP6 High Yield 
Transcription Kit (Clontech), using the control DNA in the kit as a template. RNA 
product was then purified using ammonium acetate precipitation method. mRNA 
was cap-labeled using the vaccinia virus capping enzyme in the presence of [-32P] 
GTP (Amersham), RNasin (40 unit) and S-adenosyl-methionine (SAM) (10mM) 
to label the first phosphate relative to the terminal guanosine (m7G*pppN-). The 
reaction was incubated at 37° for two hours. Cap labeled RNA was then purified 
by Qiagen RNasy purification kit. 32P-labeled cap structure was generated by 
treating the cap-labeled RNA with 1 unit nuclease S1 (Promega) for 30 minutes. 
The labeled cap analog was then extracted once by 1:1 (v: v) mixed 
phenol/chloroform and used as substrates for the decapping assays. Recombinant 
DcpS or its mutant derivatives were incubated with the labeled cap structure in 
IVDA buffer (10 mM Tris 7.5, 100 mM KOAc, 2 mM MgOAc, 2 mM DTT, 10 
mM creatine phosphate, 1 mM ATP, 0.4 mM GTP, and 0.1 mM Spermine) for 10 
min at 37oC. The reactions were stopped and extracted once with an equal mixture 
of phenol: chloroform. Products were resolved by PEI-cellulose TLC plates 
(Sigma). An aliquot of the reaction products was spotted onto the TLC and 
developed in 0.3M LiCl, 1M formic acid at room temperature. The plates were 





3. RESULTS AND DISCUSSION 
 
3.1 Overall structure description 
As shown in Figures 9a and 9b, apo-DcpS forms a symmetric homodimer 
with two protomers related by a two-fold noncrystallographic symmetry (NCS) in 
the AU. Both apo-DcpS and DcpS-m7GDP contain two distinct domains, a 
dimeric C-terminal domain (residues146-336) containing the putative active site 
and the HIT motif, and a swapped dimeric N-terminal domain (residues 40-145). 
In apo-DcpS structure, the N- and C-terminal domains are covalently connected 
through a hinge linker, which shows an identical conformation for each protomer.  
The N-domain of each protomer contains six  strands ( 1-6 in Fig 10) and 
two  helices ( 1 and 2). Two six-stranded antiparallel β sheet were formed 
through a swapped contribution of two  strands (4 and 5) and one  helix ( 1) 
by each molecule to its counterpart. Extensive interaction is generated by this 
domain-swap structure and suggests that the N-terminal dimer functions as a rigid 
body.  
Each C-terminal domain contains seven  helices ( 3 -9) and eight  strands 
( 7-14 in Fig 10), six out of which ( 7-14) form a curved, antiparallel β sheet. 
The reported active site HIT motif (275-279) located on the  strand 12. A narrow 
ligand-binding cleft (cap-binding slot) is generated by the concave surface of the 



















Fig 9. Overall structures of human DcpS: (a) A ribbon diagram of the symmetric 
apo-DcpS dimer with protomer A colored pink and protomer B colored cyan. Two 
phosphate groups are shown as stick models. (b) Orthogonal view of the apo-DcpS 
structure in (a). (c) A ribbon diagram of the asymmetric DcpS dimer in the m7GDP–
DcpS complex. A phosphate ion and the m7GDP and m7GMP molecules are shown as 
stick models. The coloring scheme is as in (a). (d) Electron densities for bound 
m7GDP, and m7GMP plus a phosphate in the closed and open conformations of the 
m7GDP–DcpS complex respectively. The Fo−Fc A-weighted map at 2.5  was 
calculated with phases from DcpS molecules only. Figure 9, Figure 11, Figure 12 








an interface between helix 7 and strands 7 and 14. But there is no other extensive 
interaction between the two C-domains.  
The symmetric dimer of apo-DcpS is strikingly different from the asymmetric 
dimer observed in the structures of DcpS with bound cap analogue. The identical 
conformations for the hinge regions observed here are markedly different from 
those in the m7GpppG-DcpS complex, wherein the hinge linker bended nearly 90° 
toward the C-terminal domain in the closed state whereas it adopts an extended 
conformation in the open state (Gu et al, 2004). In addition, in the apo-DcpS 
dimer, there are no interdomain contacts between the N- and C-terminal domains 
whereas the N- and C-terminal domains forms an extensive interface in the closed 
conformation in the m7GpppG-DcpS complex. The conformation of each 
protomer in apo-DcpS is a reminiscent of the open conformation in DcpS with 
bound cap analogue wherein few contacts are observed between the N- and C-
terminal domains. Each of the two identical active sites in apo-DcpS is occupied 
by a phosphate ion with its position close to the γ-phosphate (P-P distance of 1.0 
Å) of the bound cap analogue in the close state of the m7GpppG-DcpS complex. 
 Like DcpS with bound cap analogue, m7GDP-DcpS forms an asymmetric 
dimer (Figure 9c) with two asymmetric dimers related by a 2-fold NCS in the AU. 
Since no substantial differences are observed between the structures of the two 
m7GDP-DcpS asymmetric dimer in the AU (r.m.s.d of 0.67Å for all the 
equivalent Cα atoms), all subsequent analyses reported here use the AB dimer. 
Each of the active sites in two close conformations of m7GDP-DcpS is occupied 
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by an m7GDP molecule while that in two open conformations is occupied by an 
m7GMP molecule and a phosphate group. The overall structures of the N- and C-  
 
 
Fig 10. Structure-based Alignment of DcpS Family Members: Amino acid 
sequences of human DcpS (Hs DcpS) aligned to orthologs from mouse 
(MmDcpS), C elegans (CeDcpS), S. pombe (SpNhm1), and S. cerevisiae (ScDcs1) 
and (ScDcs2). Gaps are denoted by (· · · ·). Human DcpS amino acid numbers and 
secondary structure are indicated above the alignment. 
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terminal domains are similar to each other in the structures of apo-DcpS and 
m7GDP-DcpS (mean pair-wise Cα r.m.s.d ~0.75 Å) with the exception of the two 
hinge regions and the regions involved in cap binding. 
 
3.2 Comparison between cap-bound and unbound DcpS 
To gain insight into the DcpS structural changes upon cap binding, we 
compared the structures of apo-DcpS with both m7GDP-DcpS and m7GpppG-
DcpS. The first point is that the individual dimeric domains are similar among 
these structures. Superposition of the N-terminal domains of apo-DcpS with those 
of m7GDP-DcpS (AB dimer) and m7GpppG-DcpS give an r.m.s.d for equivalent 
Cα atoms of 0.85Å and 0.76Å, respectively (Figure 11a).  When the dimeric C-
terminal domains are superimposed, the r.m.s.d for Cα atoms is 0.73 Å and 0.90Å 
for apo-DcpS versus m7GDP-DcpS and apo-DcpS versus m7GpppG-DcpS, 
respectively (Figure 11b).   
Despite these similarities, the relative orientation of the N-terminal domain 
with respect to the C-terminal domain in apo-DcpS is dramatically different from 
those in both m7GDP-DcpS and m7GpppG-DcpS. When the dimeric C-terminal 
domain of apo-DcpS is superimposed with that of m7GpppG-DcpS, the 
orientations of the N-terminal domains differ by 37° (Figure 11c).  Similar results 
are obtained when the corresponding domains of apo-DcpS and m7GDP-DcpS are 
compared with each other. Inspection of the crystal packing ruled out the 


































Fig 11. Comparison of apo-DcpS with m7GDP–DcpS and m7GpppG–DcpS: (a) 
Stereo view of superposition of the N-terminal domain-swapped dimer (residues 40–
142) of apo-DcpS with those of m7GDP–DcpS and m7GpppG–DcpS. apo-DcpS is 
colored pink, m7GDP–DcpS is colored yellow and m7GpppG–DcpS is colored cyan. 
The same coloring scheme is used for (b) and (c). (b) Stereo view of superposition of 
the C-terminal dimeric domain (residues 142–336) of apo-DcpS with those of 
m7GDP–DcpS and m7GpppG–DcpS. Residues in apo-DcpS exhibiting large 
positional shifts upon cap binding are highlighted in magenta. m7GDP and m7GMP 
molecules in the m7GDP–DcpS complex are shown as stick models. (c) Stereo view 
of the C traces of apo-DcpS, m7GDP–DcpS and m7GpppG–DcpS. The three 
structures were superimposed, aligning the C-terminal dimeric domain using all C 
atoms. For clarity, the bound phosphate ions and nucleotides are removed. The view 








Figure 12. Comparison of the cap-binding pocket in apo-DcpS with those in 
m7GDP–DcpS and m7GpppG–DcpS: (a) Stereo view of superposition of the cap-
binding pockets in the closed states of m7GDP–DcpS and m7GpppG–DcpS with that 
of apo-DcpS. (b) Stereo view of superposition of the cap-binding pockets in the open 
states of m7GDP–DcpS and m7GpppG–DcpS with that of apo-DcpS. The m7GMP, 
m7GDP m7GpppG molecules, the phosphate ion and residues involved in interactions 
with the nucleotides are shown as stick models. The coloring scheme is the same as 




packing force. Given that the individual dimeric domains of DcpS are similar to 
each other in apo form and in complex with the cap analogue, the transition of 
symmetric to asymmetric dimer in DcpS are resulted from the rigid-body 
movement of the N-terminal domain, presumably induced by cap binding. 
Comparison of m7GDP-DcpS with m7GpppG-DcpS showed that their overall 
structure and relative domain orientations are very similar between these two 
structures with pair-wise Cα r.m.s.d of 0.62Å (Figure 11c), suggesting that 
binding of the m7Gpp portion of the cap analogue is necessary and sufficient to 
induce the orientation change of the N-terminal domain.  
In addition to the large-scale rigid-body movement of the N-terminal domain 
toward the C-terminal domain, binding of either m7GDP or m7GpppG leads to 
significant conformational changes are observed in the cap-binding pocket 
(Figure 11b). Specifically, as shown in Figure 12a, residues 170-189 and 204-
217 in the closed state moved toward each other. Consequently, Trp175 and Leu 
206 (Met206 in the apo-DcpS) shifted 2.6Å and 2.7Å respectively from their 
respective positions in apo-DcpS, thus sandwiching the m7G base between them. 
Residues Glu185, Ile179, Asp205, and Lys207 undergo displacement of 1.5Å, 1.5 
Å, 1.5 Å and 3.2Å respectively to interact with the bound cap. Ser272 and Tyr273 
flipped 180° and 90° respectively to accommodate the bound cap (Figure 12a and 
see below). In the open state, residues 204-217 also moved toward the m7G base 
with Leu206 in m7GDP-DcpS and m7GpppG-DcpS undergoing displacement of 
1.9 Å and 2.5 Å, respectively (Figure 12b). Although residues 170-189 in the 
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open state of m7GpppG-DcpS moved toward the m7G base as those observed in 
the closed state, the same region in m7GDP-DcpS moved back to its native 
positions with the largest positional shift of 3.5Å confined to residue Leu171 
(Figure 12b). Consequently, Trp175 is in an unfavorable staking position against 
the m7G base. Such conformational changes of residue 170-189 in the open state 
of m7GDP-DcpS make the cap binding less tightly. Interestingly, the 
conformations of Ser272 and Tyr273 in the open state of m7GDP-DcpS are 
similar to those in apo-DcpS but different from those in both the closed and open 
states of m7GpppG-DcpS (Figure 12b). Consistent with Ser272 being 
functionally important, mutation of Ser272 to Ala reduced the decapping activity 
by 30% (Gu et al, 2004). Other significant local conformational changes are 
observed in the hinge regions (residues 143-149) and the loop region (residues 
285-294) connecting strands β12 and β13. In the apo-DcpS, both hinge regions 
adopt an extended conformation which is different from those in both the closed 
and open states of DcpS with bound cap (Figure 11b).  Residues 285-294 are 
located in the upper part of the dimer interface in the dimeric C-terminal domain. 
In the apo-DcpS, this region is disordered for both protomers whereas it is ordered 
upon cap binding (Figure 11b), suggesting that this region may play a regulatory 
role in cap binding.  
 
3.3 Mode of ligand binding and interactions 
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Fig 9d illustrates the structure of DcpS-bound ligands. Two ligands (one 
m7GDP in the closed configuration and one m7GMP in the open configuration) 
were coordinated per DcpS dimer. The m7Gp part for the two ligands adopts 
different conformation. In the closed configuration, the m7G base and ribose are 
bound to DcpS in an extended conformation. The two phosphate groups also 
adopted an extended conformation. This ligand conformation is similar to that 
observed for N7-methyl-GDP interaction with eIF4E (Marcotrigiano et al, 1997). 
Extensive interactions were observed between m7GDP and DcpS protein. His 279, 
one of the essential histidine residues in defined HIT motif, makes direct contacts 
to  and  phosphate. His277 is the nucleophilic residue that attacks the cap  
phosphate. His 268 is proximal to  phosphate and H268N mutation disrupts the 
activity of Dcps (Gu et al, 2004). His 268 is substituted to Asn or Gln in other 
HIT proteins, indicating a unique role for His 268 in DcpS. The m7G base makes 
Van der Waals (VDW) contacts to the Tyr273 aromatic ring and is stacked 
between Trp175 and Leu 206 (Fig 13b). This sandwich structure is similar but 
slightly different from those observed in other m7G-cap-binding proteins such as 
CBP20 (Calero et al, 2002), eIF4E (Marcotrigiano et al, 1997) and VP39 (Hodel 
et al, 1998), wherein the alkylated base is sandwiched between the side-chains of 
two conserved aromatic side chains. This stacking interaction can be explained in 
terms of enhancement of - stacking enthalpy, because of charge transfer 
between the electron-deficient 7-methyl-guanine and the electron-rich indole 
groups. Mutation of Trp175 to Ala severely decreased the activity of DcpS (Gu et 
 46 
al, 2004).  Interactions were also observed between the m7G base and C-terminal 
residues Glu185, Asp205, Lys 207 and Ser272 (Fig12). In the closed 
configuration, additional contacts were observed between m7G base and residues 
from N-terminal domain. Phe108 interact with m7G through VDW contact and 
Tyr113 contacts with m7G 7-methyl group, which may contribute to the 
specificity of DcpS enzyme for N7 methylated substrate. In addition, N-terminal 
and C-terminal domain form close interface and hydrogen bond interaction was 
observed between Asn110 and Glu185. 
In the open configuration, much fewer interactions were observed. Due to the 
conformational change of the environment of ligand-binding slot (see above), 
m7G base is in an unfavorable stacking position against Trp175. The ribose and 
phosphate moieties extended away from the methylated purine toward the 
entrance to the cap-binding slot. The plane of the ribose group lies almost 
perpendicular to the plane of m7G base with the phosphate group exposing to the 
solvent region. 
 
3.4 The role of Tyr273  
Comparison of the structures suggests that Tyr273 plays an important role in 
cap binding and catalysis. The structure of m7GpppG-DcpS showed that Tyr273 
adopted the same conformation in both the closed and open states of DcpS, and 
makes Van der Waals (VDW) contact with the m7G base (Gu et al, 2004). Close 
inspection of the cap-binding pocket among the structures of apo-DcpS, m7GDP-
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DcpS and m7GpppG-DcpS showed that Tyr273 displayed remarkable 
conformational changes upon cap binding. Both Tyr273 residues in apo-DcpS 
pointed downwards whereas they flipped 90° and pointed upwards in both the 
closed and open states of m7GpppG-DcpS (Figures 12, 13a and 13b). Moreover, 
in the structure of m7GDP-DcpS, Tyr273 in the closed state adopts the same 
conformation as that in the m7GpppG-DcpS complex whereas in the open state it 
displays the same conformation as that in apo-DcpS (Figures 12, 13a and 13b). 
The conformational changes of Tyr273 in the structures of DcpS with and 
without bound ligands lead to different interactions with other amino acids. In the 
apo-DcpS and the open state of m7GDP-DcpS, Tyr273 contacts with Ile221, 
Ile219, Trp175, Val176, and His277, residues exclusively from the C-terminal 
domain via hydrophobic, VDW and stacking interactions (Figure 13a). In the 
closed states of m7GDP-DcpS and m7GpppG-DcpS, Tyr273 makes hydrophobic 
interactions with residues Trp175, Leu171, VDW contacts with residues Tyr113 
and His139 from the N-terminal, the m7G base and residues Lys142 and Tyr143 
from the hinge region (Figure 13b). In the open state of m7GpppG-DcpS, the 
flipped Tyr273 only makes hydrophobic interactions with residues Trp175 and 
Leu171 due to its solvent exposure (Figure 12b).   
To assess its functional role, Tyr273 was mutated to either Ala or Phe and 
tested for decapping activity. Substitution of Tyr273 to Ala resulted in a protein 
with 16% activity of the wild type enzyme whereas mutation of Tyr273 to Phe 



































Fig 13. Conformational changes of Tyr273 and decapping assay of its 
mutants: (a) Stereo view of the conformation of Tyr273 in apo-DcpS and its 
interactions with other protein residues. Tyr273 residues in the open states of 
m7GDP–DcpS and m7GpppG–DcpS are colored yellow and cyan, respectively. (b) 
Stereo view of the conformation of Tyr273 in the closed state of m7GDP–DcpS 
and its interactions with other protein residues. Tyr273 residues in the closed state 
of m7GpppG–DcpS and in apo-DcpS are colored cyan and pink, respectively. (c) 
Decapping assays of wild-type DcpS or DcpS mutated on Tyr273. Reaction 
products were resolved by PEI-TLC developed in 0.3 M LiCl, 1 M formic acid. 





Tyr273 plays an important role in cap binding and catalysis. Structural and 
mutational analysis of the m7GpppG-DcpS complex suggested that the enzyme 
closure is a critical step during the catalytic cycle (Gu et al, 2004). Examination 
of the structures of DcpS with bound cap showed that the flipped Tyr273 in the 
closed state interacts with the residues from the N-terminal domain and the hinge 
region, as well as with cap itself, thereby facilitating directly or indirectly the cap 
binding by contributing to the formation of the closed configuration (see above; 
Figure 13b). Mutation of Tyr273 to Ala would disrupt these interactions, thus 
affecting cap binding and catalysis. Mutation of Tyr273 to Phe would have little 
effect on its interactions with other residues in the closed state since these 
interactions are mediated by hydrophobic and VDW contacts in the closed state 
(Figure 13b), but would enhances its interaction with other amino acids in the 
predominantly hydrophobic environment in the open form of DcpS with bound 
m7GMP or in apo-DcpS (Figure 13a), thereby facilitating the product release by 
helping the enzyme back to the native state after hydrolysis. Note that Tyr273 is 
conserved among DcpS family and is replaced by Phe only in orthologs from both 
Drosophila and C. elegans (Figure 10).   
 
3.5 Coexistence of the substrate- and product-bound complexes in m7GDP-
DcpS 
m7GDP has been showed to be an efficient competitor for cap analogue in 
scavenger decapping (Cohen et al, 2004; Liu et al, 2002), suggesting DcpS binds 
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to m7GDP more tightly than the cap analogue. Although it has been reported that 
m7GDP can be converted to m7GMP by DcpS, excess protein and longer 
1incubation time are required to achieve the detectable conversion (van Dijk et al, 
2003). These observations suggest that m7GDP acts more like an inhibitor for 
DcpS rather than an optimal substrate. 
Similar to the m7GpppG-DcpS complex, binding of m7GDP to DcpS 
generated two conformational states by the rigid-body rotation of the N-terminal 
swapped dimeric domain toward one side of the C-terminal dimeric domain, and 
the induced-fit conformational changes of two regions surrounding the cap-
binding pocket (see above). Examination of the open and closed states of m7GDP-
DcpS suggests that the closed complex represents a substrate complex, while the 
open complex represents a product-bound complex. As shown in Figure 12a, in 
the closed configuration, m7GDP adopts a conformation which is similar to the 
m
7Gpp portion of m7GpppG in the closed state of the m7GpppG-DcpS complex. 
Recognition and binding of m7GDP is achieved in the same way as observed in 
the closed state of the m7GpppG-DcpS complex (Gu et al, 2004). Similar to the 
m7GpppG-DcpS complex, the interactions of m7G base, ribose and the α- and β-
phosphates of m7GDP with DcpS are mediated by the residues from both that N- 
and C-terminal domains, and the hinge region. The active site His277 which has 
been mutated to asparagines in the complex of  m7GpppG-DcpS is in an in-line 
attack position against the α-phosphate of m7GDP, with the distance of 3.43 Å 
between its Nε atom to the α-phosphate of m7GDP (Figure 12a) as observed in 
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other HIT protein family (Lima et al, 1997). His268 and His279 are located at the 
similar positions to those in the closed productive complex of m7GpppG-DcpS 
(Figure 12a). Moreover, structural comparison of DcpS with other HIT proteins 
has indicated that the active site architectures are similar among these HIT 
proteins (Gu et al, 2004). Taken together, these observations suggest that the 
closed state of m7GDP-DcpS might be a substrate-bound complex, and DcpS is 
probably to use the similar catalytic mechanism to other HIT proteins (Lima et al, 
1997) for hydrolyzing the cap structure.  
In contrast, in the open configuration, the conformation of m7GMP is different 
from the m7Gp portion of m7GpppG in the open state of the m7GpppG-DcpS 
complex. In the m7GpppG-DcpS complex, the m7Gp portion is buried deeply in 
the nucleotide binding pocket whereas m7GMP is more solvent-exposed with its 
α-phosphate group protruding to the solvent region and making no contact with 
the protein residues (Figure 12b). A phosphate ion is located in the same position 
as that in apo-DcpS in the nucleotide binding pocket, with the distance of its 
phosphorus atom to that of the γ-phosphate (corresponding to the α-phosphate of 
m7GDP) of m7GpppG of 1.3Å in the open form of the m7GpppG-DcpS complex 
(Figure 12b). The distance between the Nε atom of His277 and the phosphorus 
atom in the α-phosphate position of m7GMP is nearly 10Å, similar to the distance 
between the Nε atom of His112 and the α-phosphate of AMP observed in the 
product-bound structures of PKCI and FHIT (Lima et al, 1997). Moreover, 
residue Trp175 which is involved in stacking interaction with the m7G base 
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moves away from the m7G base due to the large conformational change of 
residues 168-175 (Figure 12b; see above), thus making less favorable stacking 
between its aromatic ring and the m7G base. Finally, Tyr273, which exposed to 
the solvent region in the open state of the m7GpppG-DcpS complex (Gu et al, 
2004), flips 90° and points to the bottom of the binding pocket with its 
conformation highly resembling those in apo-DcpS (see above). The solvent-
exposed m7GMP, the native-like conformation of Tyr273, the moving-away 
Trp175, and the distant location between His277 and the α-phosphate of m7GMP, 
suggest that the open state of m7GDP-DcpS complex is probably the product-
bound complex in which the observed m7GMP mimics the true product of 
scavenger decapping.  
 
3.6 Inherent flexibility of the N-terminal domain in apo-DcpS 
Dynamic protein motions play an important role in the catalytic function of all 
enzyme, and are implicated in events such as binding of substrates or cofactors, 
product release, or allosteric regulation (HAMMES, 1964; Karplus, 2003; Schnell 
et al, 2004). These processes are often mediated by conformational changes in the 
active site, by hinge-bending motions, or by reorientation of protein domains or 
entire protein subunits. The symmetric to asymmetric transition of DcpS induced 
by cap binding implies that the decapping reaction catalyzed by DcpS may be a 
dynamic process. 
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It has been long recognized that the variations in crystallographic temperature 
factors (B-factors) reflect the amplitude of motions varies along the polypeptide 
chain, as well as between different liganded complexes of the enzyme. The 
averaged B factors of main-chain atoms for each residue for apo-DcpS and 
m7GDP-DcpS have been calculated and shown in Figure 14. Strikingly, the 
whole N-terminal domain rather than a particular region in it has substantially 
higher B factors than that of the C-terminal domain in apo-DcpS. In contrast, the 
B factors differences between the N- and C-terminal domains are much smaller 
for m7GDP-DcpS. The averaged B factors of all the main-chain atoms for the N- 
and C-terminal domains in apo-DcpS are 46.2Å2 and 16.4 Å2, respectively 
whereas those for the N- and C-terminal domains in m7GDP-DcpS are 30.7Å2 and 
14.5Å2, respectively. These results suggest that without bound ligand, the N-
terminal domain is rather flexible and unstable while the C-terminal domain is 
relatively stable, and binding of ligand to DcpS decreases the flexibility of the N-
terminal domain. Consistent with this notion, the N-terminal is connected by the 
flexible hinge and has no contact with the C-terminal domain in the apo-DcpS 
whereas upon cap binding, the N-terminal domain rotated with respect to the C-
terminal domain and contacted one side of the dimeric C-terminal domains, thus 
creating the closed and open states simultaneously. The proposed catalysis 
mechanism of DcpS requires that the closed and open states must be alternated in 












































Fig 14. B-factors of apo-DcpS and m7GDP-DcpS: (a) Plot of the main-chain B-
factors (Å2) of protomers A (pink) and B (blue) of apo-DcpS. (b) Plot of the main-
chain B-factors (Å2) of protomers A (blue), B (pink), C (green), and D (orange) of 
the m7GDP-DcpS complex.  
 
alternating nature of this mechanism requires the N-terminal domain must be 
flexible and in a dynamic state ready for substrate binding and product release.  
 
3.7 Structural homology 
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Search the Protein Data Bank for structurally related proteins using DALI 
(Holm & Sander, 1993) revealed structural homology between the C-terminal 
domain of DcpS (including residues 146-336) and several proteins. In order of 
ranking, structural similarity was observed for human protein kinase inhibitor 
(protein kinase C interacting protein PKCI) (PDB1kpf; 2.1 Å rmsd with 18% 
sequence identity over 100 residues; Z-score of 10.3) (Lima et al., 1997), human 
fragile histidine triad protein (FHIT) (PDB1fit; 2.6 Å rmsd with 13% sequence 
identity over 91 residues; Z-score of 6.3) (Lima et al, 1997), nit-fragile histidine 
triad fusion protein (NIT-FHIT) (PDB1ems; 2.6 Å rmsd with 17% sequence 
identity over 89 residues; Z-score of 6.2) (Pace et al, 2000), and galactose-
phosphate uridylyltransferase (GalT) (PDB1guq; 4.5 Å rmsd with 13% sequence 
identity over 116 residues; Z-score of 4.1) (Thoden et al, 1997). 
Proteins PKCI, FHIT, and NIT-FHIT are members of HIT family and also 
exist as dimers and form a continuous 10-stranded anti-parallel -sheet across the 
dimeric interface with each protomer contributing a five-stranded -sheet. Each 
protomer protein contains an active pocket with the functional HIT motif.  
Interestingly, those HIT protein dimers are topologically related to a monomer of 
galactose-phosphate uridylyltransferase (GalT) (Brenner et al., 1997), a family of 
proteins that catalyze nucleotidyl-transfer activities using a similar active histidine 
residue. Despite all these similarities regarding overall folding and active site 
architecture between DcpS and HIT members and GalT, DcpS still distinct from 
those proteins in that DcpS does not form the 10-stranded anti-parallel -sheet in 
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the dimeric interface. This is consistent with the observation that the C-terminal 
domain alone of DcpS is not enough for decapping function, indicating the 
distinction between these protein families. 
A Protein Data Bank search using DALI (Holm an Sander, 1993) against N-
terminal of DcpS (including residues 40-145) found several structurally related 
proteins. In order of ranking, structural similarity was observed for rec- 
serine/threonine kinase fragment (PDB1mrv; 2.3 Å rmsd with 11% sequence 
identity over 47 residues; Z-score of 4.4) (Huang et al, 2003), yeast antiviral 
protein ski8 (PDB1s4u; 3.3 Å rmsd with 10% sequence identity over 48 residues; 
Z-score of 4.4) (Cheng et al, 2004), and latexin (carboxypeptidase inhibitor) 
(PDB1wnh,  2.2 Å rmsd with 6% sequence identity over 48 residues; Z-score of 
3.7) (Aagaard et al, 2005). Those proteins all mainly contain several -sheets. 
Although DcpS shows structurally similarity with those proteins, the unique 
domain-swapped topology and architecture is distinct from all of them. Since 
those homologous structures belong to various protein families and share no 
common function, it is hard to get clues of the function of DcpS N-terminal 
domain through this comparison. 
 
3.8 Mechanistic implications 
The set of structures available for DcpS now allows a model for the cycle of 
substrate binding, catalysis and product release to be proposed. In the absence of 
any substrate, DcpS is in a symmetric open state, with both active sites available 
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for substrate binding. Upon interaction with a cap moiety in one of the active sites, 
that side of the protein adopts a closed state, which involves a large-scale rotation 
of the N-terminal head domain, and local structural changes in the cap-binding 
pocket to stabilize the substrate binding. Hydrolysis of the cap structure leads to 
conformational changes in the cap-binding pocket, similar to what is seen in the 
open configuration of the m7GDP–DcpS structure. These changes would be 
predicted to weaken the interaction of the m7GMP product with the enzyme and 
enhance product release.  
It is currently unclear how the two active sites interact during cycles of cap 
structure hydrolysis by DcpS, and particularly how substrate binding in one site 
relates to product release from the other. The proposed catalytic mechanism (Gu 
et al, 2004) requires that the closed and open states are alternated via 30 Å 
conformational changes; while one side closes to promote catalysis during cap 
cleavage, the other side is forced open to permit binding of a short capped mRNA. 
However, this model is unlikely, given that the intermediate state where both sites 
are closed would require substantial distortion of the N-terminal domains, which 
would presumably be energetically unfavorable. Moreover, the two sites do not 
appear to be connected mechanistically, since we do not observe substantial 
changes in the interface of N-terminal and C-terminal domains between apo-DcpS 
and the open states of both m7GDP-bound and m7GpppG-bound DcpS structures, 
which suggests that the two active sites act relatively independently of each other 
at a structural level. Comparison of structures showed that the two equal 
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conformations of apo-DcpS differ dramatically from that of the closed state but 
are very similar to that of the open state in the structures of DcpS with bound cap. 
In apo-DcpS, the distance between the N- and C-terminal domain is 26Å (Cα-Cα 
distance between residues 111 and 175) whereas those in the closed and open 
states of DcpS are 6Å and 36Å respectively. Closure of the enzyme leads to 20Å 
movement of the N-terminal domain resulted from the rigid-body rotation of the 
N-terminal domain with respect to the C-terminal domain. In addition, the cap-
binding pocket is closed responding to the substrate binding and coordinates with 
the movement of the N-terminal domain to promote the catalysis in the closed 
state whereas in the open state, the openness of the cap-binding pocket and the 
distant location between the N-and C-terminal domains is poised to facilitate the 
release of the product. During the catalysis cycle of DcpS, flexibility appears to 
be a characteristic of the cap-binding pocket and the N-terminal domain of DcpS. 
Such dynamic conformational changes in DcpS ensure that enzyme could catalyze 
the hydrolysis of the cap structure substrate with high efficiency and specificity.   
The flexible nature of the N-domain relative to the C-domain in the DcpS 
structures suggest a catalytic cycle wherein any transition between open and 
closed states on opposing sides of the dimer requires an intermediate form similar 
to the apo-DcpS structure, where both sites are in the open configuration. In this 
view, the binding of substrate to one site is coupled with hydrolysis and release of 
the product in the other site in a kinetic manner. 
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A key unresolved question concerns how access of the cap-binding site of 
DcpS is regulated. Such regulation is necessary to ensure only residual cap 
structure substrate can be degraded, thereby preventing the premature decapping 
on the capped mRNA by DcpS. Biochemical studies has demonstrated that DcpS 
is a modular protein requiring both the core HIT fold at the C-terminal domain 
and the N-terminal domain for cap binding and hydrolysis (Liu et al, 2004). The 
structures of DcpS with bound cap analogues revealed two distinct and mutually 
exclusive active sites (Gu et al, 2004). The subsequent mutagenesis studies 
suggested that DcpS must close to promote catalysis as disruption of the contacts 
in the closed conformation impaired the enzyme activity.  Based on these results, 
a model has been proposed, in that DcpS is unable to bind the 5’ end of large 
capped mRNA due to the increased entropy inherent to larger and more flexible 
RNA molecules, thus blocking substrate binding, closure, and enzyme activation 
until RNA length and entropy is reduced via 3’-5’ degradation. More recently, Liu 
et al. (2004) showed that DcpS is capable of binding long capped mRNA with Kd 
of 1.2µM but has 2500-fold lower capacity to hydrolyze the capped RNA relative 
to the cap structure substrate. These results suggest that DcpS can bind the cap on 
larger mRNA molecules with reasonable affinity, but the enzyme closure and 
activation are probably restricted by a steric hindrance or increased entropy of 
larger RNA or both.  
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Figure 15. Solvent-accessible surface and electrostatic potential of apo-DcpS: 
The Figure reveals the positive electrostatic potential located in the channel 
between the N-terminal and C-terminal domains of apo-DcpS. m7GpppG of the 
m7GpppG–DcpS complex superimposed on apo-DcpS is shown as a stick model. 
This Figure was produced using GRASP (Nicholls, A et al, 1991). 
 
Consistent with the finding that DcpS can bind larger capped mRNA; 
electrostatic potential mapping on the molecular surface of apo-DcpS reveals a 
prominent positively-charged patch located on the central channel of the enzyme 
(Figure 15). This channel is sufficiently wide for binding a single strand mRNA 
molecule. Further experimental data are required to check whether this channel 
indeed is involved in mRNA binding.  
One intriguing possibility is that a long RNA might bind in the putative RNA 








and forming an active catalytic site. In this model, only mRNAs that are short 
enough to interact with only one site at a time would be substrates for DcpS. 
 
3.9 Conclusion 
In conclusion, the three-dimensional structures of both apo-DcpS and m7GDP-
DcpS protein-nucleic acid complex demonstrate the cap binding properties of 
human DcpS protein. DcpS is a module protein containing a dimeric C-terminal 
domain and a swapped N-terminal domain. An unusual large-scale 
conformational change of whole N-terminal domain upon ligand binding was 
observed. Through structural comparisons, a mechanism for DcpS catalysis of 
residual structure was proposed. Our work also provides a starting point for 
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